Evaluation of 73 Enlisted Patients for Liver Transplant with Unknown Etiology Reveals a Late-Diagnosed Case of Lysosomal Acid Lipase Deficiency
Authors:
- Karina Lucio de Medeiros BastosKBKarina Lucio de Medeiros Bastos
- Bruno de Oliveira StephanBSBruno de Oliveira Stephan
- Bianca Domit Werner LinnenkampBLBianca Domit Werner Linnenkamp
- Larissa Athayde CostaLCLarissa Athayde Costa
- Fabiana Roberto LimaFLFabiana Roberto Lima
- Laura Machado Lara CarvalhoLCLaura Machado Lara Carvalho
- Rachel Sayuri HonjoRHRachel Sayuri Honjo
- Uenis TannuriUTUenis Tannuri
- Ana Cristina Aoun TannuriATAna Cristina Aoun Tannuri
- Chong Ae KimCKChong Ae Kim
Open Access
- 8 August 2024
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8648
Abstract
Lysosomal acid lipase deficiency (LALD) varies from a severe infantile-onset form (Wolman disease) to a late-onset form known as cholesteryl ester storage disease (CESD), both of which are autosomal recessive disorders caused by biallelic LIPA pathogenic variants. We evaluated seventy-three patients enlisted for liver transplant (LT) at Instituto da Criança (HCFMUSP—Brazil) who were subjected to LAL activity measurement and LIPA Sanger sequencing analysis, resulting in a positive LALD diagnosis for only one of these individuals. This LALD patient presented recurrent diarrhea, failure to thrive, hepatomegaly, and dyslipidemia at the age of 4 months and liver failure by the age of 13 years. The LALD diagnosis confirmation was conducted at 24 years old due to low levels of LAL enzyme activity. The causal homozygous variant LIPA(NM_000235.4):c.266T>C(p.Leu89Pro) was identified, but the patient had already undergone his first LT at 18 years with several rejection episodes. Despite beginning treatment with sebelipase alfa at 26 years old (total of five infusions), this patient died at 28 years from complications after his second liver transplant. LALD is an important differential diagnosis in cases presenting with hepatomegaly, elevated liver enzymes, and dyslipidemia. Detecting low/absent LAL activity and identifying the LIPA causal variant are essential for diagnosis and specific treatment, as well as for appropriate genetic counseling. Early diagnosis, along with sebelipase alfa therapy, may improve the prognosis of affected patients.Keywords
This publication has 37 references indexed in Scilit:
- Living-Donor Liver Transplantation for Late-Onset Lysosomal Acid Lipase DeficiencyJournal of Clinical and Experimental Hepatology, 2022
- Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelinesHuman Mutation, 2020
- Mangel an lysosomaler saurer Lipase (LAL-D)Der Pathologe, 2017
- Sebelipase Alfa: A Review in Lysosomal Acid Lipase DeficiencyAmerican Journal of Cardiovascular Drugs, 2016
- REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense VariantsThe American Journal of Human Genetics, 2016
- Sebelipase Alfa: First Global ApprovalDrugs, 2015
- Frequency of the Cholesteryl Ester Storage Disease Common Lipa E8sjm Mutation (C.894G>A) in Various Racial And Ethnic GroupsHepatology, 2013
- A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2Clinica Chimica Acta, 2012
- Orthotopic Liver Transplantation in an Adult with Cholesterol Ester Storage Disease2012
- Successful treatment of Wolman disease by unrelated umbilical cord blood transplantationEuropean Journal of Pediatrics, 2006